Overview

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-09-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I). This study will examine the effects Venetoclax has on participants when it is given in combination with BR-I.

Phase:

Early Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Bendamustine Hydrochloride
Rituximab
Venetoclax